Introduction
Platelet-derived growth factor (PDGF), endothelial growth factor (EGF), insulin-like growth factor (IGF-I), transforming growth factor-β-1 (TGF-β-l), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and basic fibroblast growth factor (bFGF) (1,2) that contain platelet-rich plasma (PRP) are frequently used to treat musculoskeletal injuries (3, 4) .
Like other injections, PRP applications could be painful, and clinicians may prefer to apply local anesthetics before or after injections for relieving pain (5) . There are conflicting results concerning the interaction of local anesthetics and PRP (5, 6) . In addition, nonsteroidal antiinflammatory drug (NSAID) usage is also not uncommon in athletes with acute or chronic pain (7, 8) . NSAIDs are known to inhibit platelet aggregation by inhibiting cyclooxygenase (COX) enzymes ( Figure 1) ; however, to our best knowledge, there are no clear data about whether NSAIDs affect platelet activity. Since PDGF and VEGF stimulate cell proliferation and angiogenesis and contribute to tissue regeneration (9, 10) , the research questions of this study were as follows: whether reversible COX-1 and COX-2 inhibitors, as well as irreversible acetylsalicylic acid (ASA), affect serum PDGF and VEGF concentrations, and whether PDGF and VEGF levels of PRP correlate with each other according to different doses of the drugs used in the study.
Materials and methods

Design
A cross-sectional in vitro controlled experiment was designed. Independent variables were groups (n = 6) ( Table) , and dependent variables were PDGF-AB and VEGF levels of PRP measured with ELISA.
Participants
Twenty healthy males voluntarily participated. The average age of participants was 24.0 ± 3.2 years (range: Background/aim: Platelet-rich plasma (PRP) application has gained widespread interest for musculoskeletal injuries. Nonsteroidal antiinflammatory drugs are frequently used in sports medicine before and/or after PRP application. Our study seeks to determine whether serum levels of platelet-derived growth factor-AB (PDGF-AB) and vascular endothelial growth factor (VEGF) levels of PRP would be affected by nonsteroidal antiinflammatory drugs. ). Blood or PRP specimens of 250 µL taken in polypropylene tubes were loaded into the device for cellular count. Pearson's correlation coefficient for platelet counts of PRP and whole blood samples was r P = 0.91. These data indicate that PRP preparations were successful (11).
NSAIDs and supernatant collection
Reversible COX-1 and COX-2 inhibitor diclofenac, reversible COX-2 inhibitor meloxicam, and irreversible COX-1 inhibitor ASA were added to the test tubes containing PRP.
Each PRP sample was divided into 6 tubes. We added two different dosages of diclofenac (Diclomec, Abdi İbrahim Pharmaceuticals, İstanbul, Turkey) and meloxicam (Melox, Nobel İlaç, Düzce, Turkey) into tubes to obtain 0.5 µg mL -1 and 2.5 µg mL -1 final concentrations of diclofenac and meloxicam (12) (13) (14) in order to evaluate the dose response. The same volumes of ASA (a final concentration of 450 µm) and saline were added to other PRP samples to have ASA and medicine-free groups as the control (14-16). All test tubes were incubated for 20 min at room temperature. PRP clots were formed by adding 27.5 µL of 10% calcium chloride to 0.55 mL of PRP. Clots were allowed to retract for 20 to 30 min and were then centrifuged at 1000 × g for 10 min (Hettich Mikro 200R Centrifuges, Tuttlingen, Germany). Supernatants were stored at -20 °C for subsequent ELISA analysis. 2.5. Growth factor concentration measurements PDGF-AB and VEGF concentrations were measured using a Quantikine Colorimetric Sandwich ELISA kit (R&D Systems Inc., Minneapolis, MN, USA). All samples were assayed in duplicate (SpectraMax Plus 384 Microplate Reader, Sunnyvale, CA, USA) (3).
Statistical analysis
Results were expressed as averages with standard deviations. A Shapiro-Wilk test was used to check the homogeneity of groups. A Friedman test was used to assess the effect of medicines on VEGF levels, and a one-way analysis of variance was used to compare the distribution of PDGF-AB results. Statistical differences between groups were accepted for P < 0.05 (StatGraphics Plus, Manugistics Group, Rockland, MD, USA).
Results
After exposure to PRPs with each dose of the medicines, the measured growth factor levels were similar among groups (P > 0.05) (Figures 2 and 3) . PDGF-AB and VEGF serum levels correlated significantly (P < 0.05) with each other when all PDGF-AB and VEGF data from whole samples were pooled (Figure 4 ).
Discussion
There is no clear evidence whether NSAIDs affect platelet activity in PRP injections. The research question of this study was whether reversible and irreversible COX inhibitors would decrease PDGF and VEGF serum levels after PRP solutions were exposed to medicines.
Our results showed that adding diclofenac or meloxicam in vitro with the dosages used in this study did not change PDGF-AB and VEGF serum levels in the PRP solution. Although ASA is known to irreversibly inhibit platelet aggregation, adding ASA to the PRP solution also did not change the amount of growth factors.
Increased cellular proliferation and vascularity are the most important properties that PRP promotes in the healing of musculoskeletal tissues, positively contributing to the overall repair process. PDGF-AB plays a major role in the chemotactic activity of PRP, along with other PDGF ligands (17) . It is also a potent mitogen for connective tissue cells and enhances fibroblast proliferation. VEGF is a powerful stimulator of angiogenesis, building new vasculature to bring additional extrinsic cells, nutrients, and growth factors to injured areas (18, 19) . Therefore, we specifically analyzed these two growth factors (PDGF-AB and VEGF).
Previous studies have assessed the antiaggregant effects of diclofenac, meloxicam, and ASA in vitro. Yokoyama et al. noted a 20% inhibition of platelet aggregation by adding diclofenac and meloxicam. In the same study, the inhibition rate of platelet aggregation was 60% to 80% with ASA (16) . In another study, a different dosage of diclofenac (0.1-0.8 µg mL -1 ) and ASA (100 µm) were tested (14) . Diclofenac resulted in a dose-dependent increase in the inhibition of platelet aggregation, and the inhibition rate was much higher for ASA. We expected that NSAIDs and ASA would suppress platelet secretion and growth factor levels; however, such a result was not obtained. Adding calcium to a PRP solution initiates the coagulation cascade and, as a result, thrombin is formed (3) . Thrombin binds to protease-activated receptors (PAR-1) and initiates platelet activation through the phospholipase C pathway. When activated, platelets secrete their granule contents and release growth factors (20, 21) . Findings in this study could be explained by the highly stimulating effect of thrombin on platelet secretion, which may hinder the antiaggregant effects of NSAIDs and ASA.
Recently, two studies conducted by Anitua et al. evaluated the serum growth factor levels (including PDGF-AB and VEGF) and the proliferation capabilities of PRPs in cell cultures obtained from chronic ASA users (22, 23) . Similar to our findings, there were no significant differences for the amounts of growth factors and proliferation rates compared with the control groups.
Our study has shown that the growth factor levels of the samples were not correlated with the number of platelets. These findings support the result of Weibrich et al., who evaluated 115 PRP samples and could not find any relation between the platelet counts and the levels of growth factor (24) . These data support the notion that platelet counts in a PRP solution may not be the only method to estimate platelet secretion quality.
PDGF-AB and VEGF are found in alpha granules and secreted with the other growth factors described above. Weibrich et al. (24) showed that there is a correlation between PDGF-AB and TGF-β1 (r S = 0.78). Therefore, they concluded that PDGF-AB serum levels could be used in estimating TGF-β1 serum levels. To support that notion, we found a significant correlation (P = 0.0001, r = 0.4) between the serum levels of PDGF-AB and VEGF when all 6 groups were included in tests measuring the relationship of these growth factors.
The study has some limitations. First, these medications were tested only in vitro. Thus, we do not know if diclofenac, meloxicam, or ASA would have any effect on the levels of growth factors in vivo. Second, we only evaluated the levels of PDGF-AB and VEGF. Therefore, we do not know if other growth factors stored in platelets could be affected. In order to eliminate the amount of growth factors coming from leukocytes, we used a leukocyte-reduced PRP preparation technique defined by Anitua for minimizing the leukocyte effect (3, 25) . The number of leukocytes in our PRP solutions was higher (1620 ± 771.57 µL -1 ) than what Anitua reported before (3) . Nonetheless, the previous literature has shown that leukocytes have a poor growth factor content (26) . Therefore, we do not think that the number of leukocytes in our study affected our results. According to our study, diclofenac, meloxicam, and ASA did not affect PDGF-AB and VEGF levels of PRP in vitro. However, we cannot extrapolate from the information gained here for clinical practice. Studies that obtain PRPs from donors who are prescribed NSAIDs need to examine their effects on PRP secretion in vivo.
